Figure 3
AdCMV.NK4 reduces clinical score and ankle swelling. Arthritis was induced by a single intraperitoneal injection of the β-glucan laminarin (45 mg). AdCMV.NK4 (1 × 109 plaque-forming units (pfu); n = 8; filled squares) or AdCMV.LacZ (1 × 109 pfu; n =8; filled diamonds) was administered intravenously at the time of laminarin injection. (A) Changes in arthritis scores were monitored over the course of 60 days. (B) The ankle swelling in mice treated with AdCMV.NK4 (1 × 109 pfu) or AdCMV.LacZ was examined on day 60 after induction of arthritis. (C) To determine the therapeutic effectiveness of this treatment on arthritis, we introduced AdCMV.NK4 (1 × 109 pfu; n = 8) or AdCMV.LacZ (1 × 109 pfu; n = 8) into SKG mice 1 month after β-glucan injection, and the ankle swelling was examined on day 60 after induction of arthritis (C). Arthritis scores were monitored by inspection as follows: 0, no swelling; 0.1, swelling of one toe joint; 0.5, mild paw swelling; and 1.0, severe paw swelling. The results are expressed as the means ± SD. *P < 0.05 vs SKG mice given AdCMV.NK4. Representative data of two separate experiments are shown.